Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Grants NorDiag Exclusive European WAVE Rights

NEW YORK, Feb. 9 (GenomeWeb News) - Transgenomic and NorDiag announced today that they have signed an exclusive license and supply agreement to collaborate in colorectal and pancreatic cancer diagnostics.

 

Terms of the deal call for Transgenomic to give NorDiag exclusive European commercial rights to use its Wave system in exchange for an undisclosed licensing fee and commitment to annual purchases by NorDiag.

 

NorDiag uses the Wave system in its Genefec test. The platform is "integral to the automation of the Genefec test," said the companies in a statement.

 

NorDiag has offices in London and Bergen, Norway. The Genefec test is available as a clinical diagnostic in Norway and Sweden.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.